These findings identify RIPK1, RIPK3, and MLKL as potential molecular targets to potentially limit tissue injuries in silicosis, TiO2-induced lung injury, cholesterol embolism, oxalate-/phosphate-/urate-nephropathy, gout, as well as other crystallopathies. Here, MLKL is linked to total cholesterol measurement.